Core Viewpoint - 基石药业-B's stock rose over 5% following the approval of a new indication for Shugli monoclonal antibody by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for treating adult patients with inoperable stage III small cell lung cancer (NSCLC) [1] Group 1: Company Developments - 基石药业-B's stock increased by 5.12%, reaching HKD 6.36, with a trading volume of HKD 23.93 million [1] - The MHRA approved Shugli monoclonal antibody for use as a monotherapy in adult patients with NSCLC who have PD-L1 expression ≥1%, no EGFR sensitive mutations or ALK/ROS1 genomic alterations, and have not shown disease progression after platinum-based chemoradiotherapy [1] - This approval marks the second indication for Shugli monoclonal antibody in the UK, following a previous approval from the European Commission [1] Group 2: Market Expansion - Shugli monoclonal antibody has secured four commercialization partnerships across Europe, the Middle East, Africa, and Latin America, covering over sixty countries and regions [1] - The company is actively advancing its commercialization efforts in international markets [1]
港股异动 | 基石药业-B(02616)涨超5% 舒格利单抗III期非小细胞肺癌新适应症获英国...